Amneal Pharmaceuticals, Inc.

For the period ended Mar 31, 2026. Filed May 7, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 7, 2026

AMRX$21.28+5.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations

(unaudited; in thousands, except per share amounts)

	Three Months Ended March 31,
	2026	2025
Net revenue	$722,519	$695,420
Cost of goods sold	402,406	439,529
Gross profit	320,113	255,891
Selling, general and administrative	138,860	118,288
Research and development	38,383	40,040
Intellectual property legal development expenses	1,542	1,767
Acquisition costs	5,153	—
Restructuring and other charges	650	571
Charges related to legal matters, net	694	—
Other operating income	(6,941)	(5,122)
Operating income	141,772	100,347
Other (expense) income:
Interest expense, net	(53,361)	(56,939)
Foreign exchange (loss) gain, net	(7,800)	4,247
Loss on refinancing	(3,510)	—
Decrease (increase) in tax receivable agreement liability	2,333	(10,687)
Other income, net	742	518
Total other expense, net	(61,596)	(62,861)
Income before income taxes	80,176	37,486
Provision for income taxes	2,176	12,868
Net income	78,000	24,618
Less: Net income attributable to non-controlling interests	(15,744)	(12,423)
Net income attributable to Amneal Pharmaceuticals, Inc.	$62,256	$12,195
Net income per share attributable to Amneal Pharmaceuticals, Inc.’s Class A common stockholders:
Basic	$0.20	$0.04
Diluted	$0.19	$0.04
Weighted-average common shares outstanding:
Basic	316,023	311,054
Diluted	328,933	323,961

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.